Pall Signs Biopharm Separation Technology Pact

Pall Corporation, a provider of filtration, separation, and purification products and services, has signed an exclusive license for acoustic wave separation (AWS), a technology from FloDesign Sonics (FDS) for cell-culture clarification for fed-batch and perfusion applications. The AWS technology enables continuous removal of the cells in a closed system without centrifugation in the biologics manufacturing. The technology complement Pall’s STAXT depth filtration products to enable continuous clarification of cell culture, enabling integration of the bioreactor with downstream processing.

The AWS technology works by applying acoustic forces across a flow channel to generate a three-dimensional standing wave. When a cell culture passes through the flow channel, the cells are trapped at the nodes of the acoustic waves and then aggregate, culminating in their precipitation from suspension as their buoyancy decreases. Important features are no temperature increase, no damage to cells or proteins, and the process works in a robust manner at high yields, according to Pall.

The integration of the AWS technology expands the portfolio of continuous bioprocessing and single-use products offered by Pall, which recently announced the acquisition of the BioSMB multicolumn continuous chromatography platform from Tarpon Biosystems.

The AWS technology works by applying acoustic forces across a flow channel to generate a three-dimensional standing wave. When a cell culture passes through the flow channel, the cells are trapped at the nodes of the acoustic waves and then aggregate, culminating in their precipitation from suspension as their buoyancy decreases. Important features are no temperature increase, no damage to cells or proteins, and the process works in a robust manner at high yields, according to Pall.

Source: Pall Corporation

Leave a Reply

Your email address will not be published. Required fields are marked *